ICP-248 With Azacitidine
A Phase 1 Study of ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies.
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 266 patients (estimated)
- Tags
- BCL-2 Inhibitor
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 2226
- NCT Identifier
- NCT06656494
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.